Last reviewed 2026-04-20 · How we verify

Clorotrisin (CHLOROTRIANISENE)

Clorotrisin (CHLOROTRIANISENE) is a small molecule drug that targets the estrogen receptor. It is classified as a chlorotrianisene and is used to treat conditions associated with estrogen activity. As an off-patent medication, it is available as a generic product. The commercial status of Clorotrisin is off-patent, with one generic manufacturer available. Key safety considerations are not well-documented due to the lack of FDA approval and available information.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Drug interactions

• fosphenytoin
• phenobarbital
• phenytoin

Key clinical trials

• IIT2025-03-YANG-LIFT-HCC (PHASE2)
• TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk (PHASE2)
• Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca (NA)
• Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (PHASE2)
• GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring
• IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) (PHASE2)
• 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer (PHASE1)
• A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.